Table 3.
Multivariable analysis (After Matching) of factors associated with overall survival
| Variable | HR | 95 % CI | P-value |
|---|---|---|---|
| Stage | |||
| Stage IIB/C | 1.52 | (1.44,1.60) | <.0001 |
| Stage IIIA | 1.00 | – | – |
| Age | |||
| 18–49 | – | – | – |
| 50–64 | 1.24 | (1.06, 1.44) | 0.006 |
| 65–74 | 1.70 | (1.44, 1.99) | <.0001 |
| 75 and more | 2.85 | (2.43, 3.35) | <.0001 |
| Race/Ethnicity | |||
| White | 1.00 | – | – |
| Black | 1.18 | (1.09, 1.28) | <.0001 |
| American Indian, Aleutian, or Eskimo | 1.15 | (0.71, 1.87) | 0.57 |
| Asian or Pacific Islander | 0.76 | (0.62, 0.94) | 0.01 |
| Other | 0.73 | (0.45, 1.18) | 0.20 |
| Facility Type | |||
| Community cancer program | 1.29 | (1.18, 1.40) | <.0001 |
| Comprehensive community cancer center | 1.15 | (1.08, 1.22) | <.0001 |
| Academic research program | 1.00 | – | – |
| Facility Location | |||
| New England | 1.00 | (0.88, 1.14) | 0.98 |
| Mid Atlantic | 0.99 | (0.90, 1.10) | 0.91 |
| South Atlantic | 0.95 | (0.87, 1.05) | 0.32 |
| East North Central | 0.95 | (0.87, 1.05) | 0.31 |
| East South Central | 0.98 | (0.87, 1.11) | 0.79 |
| West North Central | 1.02 | (0.91, 1.15) | 0.68 |
| West South Central | 0.96 | (0.85, 1.08) | 0.46 |
| Mountain | 0.91 | (0.79, 1.06) | 0.25 |
| Pacific | 1.00 | – | – |
| Urban/Rural Location | |||
| Metro ≥1 million | 1.00 | – | – |
| Metro 250 k to 1 million | 1.02 | (0.96, 1.08) | 0.56 |
| Urban <250 k | 0.95 | (0.87, 1.03) | 0.22 |
| Urban ≥ 20 k adjacent metro | 0.98 | (0.87, 1.11) | 0.75 |
| Urban ≥ 20 k not adjacent metro | 0.89 | (0.73, 1.08) | 0.24 |
| Urban <20 k adjacent metro | 0.98 | (0.87, 1.10) | 0.68 |
| Urban <20 k not adjacent metro | 1.10 | (0.94, 1.28) | 0.25 |
| Rural <2500 adjacent metro | 0.93 | (0.72, 1.21) | 0.57 |
| Rural <2500 not adjacent metro | 0.90 | (0.71, 1.14) | 0.38 |
| Comorbidities | |||
| 0 | 1.00 | – | – |
| 1 | 1.26 | (1.19, 1.33) | <.0001 |
| 2 | 1.65 | (1.53, 1.77) | <.0001 |
| Primary Site | |||
| Cecum | 1.00 | – | – |
| Ascending Colon | 1.00 | (0.93, 1.08) | 0.99 |
| Hepatic Flexure | 1.02 | (0.90, 1.16) | 0.72 |
| Transverse Colon | 0.97 | (0.88, 1.06) | 0.45 |
| Splenic Flexure | 1.16 | (0.99, 1.35) | 0.07 |
| Descending Colon | 1.06 | (0.95, 1.19) | 0.31 |
| Sigmoid Colon | 0.98 | (0.92, 1.05) | 0.58 |
| Overlapping Lesions | 0.92 | (0.70, 1.20) | 0.54 |
| Not Otherwise Specified | 1.39 | (1.17, 1.66) | 0.0002 |
| Readmission within 30 days of Surgery | |||
| Not readmitted | 1.00 | – | – |
| Readmitted | 1.21 | (1.12, 1.31) | <.0001 |
| Grade | |||
| Well differentiated | 1.00 | – | – |
| Moderately differentiated | 1.07 | (0.98, 1.16) | 0.12 |
| Poorly differentiated | 1.20 | (1.09, 1.32) | 0.0002 |
| Undifferentiated, anaplastic | 1.21 | (1.00, 1.47) | 0.05 |
| Regional Lymph Nodes Examined | |||
| 0–11 | 1.30 | (1.23, 1.37) | <.0001 |
| 12–90 | 1.00 | – | – |
| Chemotherapy | |||
| Yes | 1.00 | – | – |
| No | 2.24 | (2.11, 2.37) | <.0001 |
| Surgical Margins | |||
| No residual tumor | 1.00 | – | – |
| With Residual tumor | 1.56 | (1.29, 1.89) | 0.003 |